A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Concurrent Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
This is a Phase I/II, single-arm, open-label, exploratory study aimed at evaluating the safety, tolerability, and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with gemcitabine and iparomlimab-toripalimab in patients with borderline resectable pancreatic cancer. The study is divided into two phases: The Phase Ib dose-escalation phase will use a "3+3" design to explore the maximum tolerated dose (MTD) of SBRT (6 Gy×5 F, 7 Gy×5 F, 8 Gy×5 F) combined with gemcitabine and iparomlimab-toripalimab. The Phase II phase will further evaluate the efficacy and safety of this combination regimen based on the SBRT dose determined in Phase Ib. The primary efficacy endpoint is the R0 resection rate.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a single-center, Phase I/II, single-arm, open-label, exploratory clinical study initiated by Tianjin Medical University Cancer Institute & Hospital.
Phase Ib (Dose-Escalation Phase): A classic "3+3" design will be used to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of SBRT. Three pre-specified SBRT dose levels are planned: 6 Gy×5 F, 7 Gy×5 F, and 8 Gy×5 F. All subjects will concurrently receive standard-dose gemcitabine chemotherapy and iparomlimab-toripalimab immunotherapy. The DLT observation period is 6 months from the start of treatment, focusing on Grade 3 or higher SBRT-related toxicities in organs at risk. The MTD is defined as the highest dose level at which ≤33% (i.e., no more than 1 out of 6) of subjects experience a DLT during the observation period.
Phase II (Expansion Phase): Based on the SBRT MTD determined in Phase Ib, preoperative neoadjuvant therapy will be administered in combination with gemcitabine and iparomlimab-toripalimab. The treatment cycle consists of 3 cycles, expected to last 12 weeks. Tumor assessment will be performed after 2 cycles of treatment. If there is no disease progression and adverse reactions are tolerable, treatment will continue. Surgical resection will be performed 3-4 weeks after the last dose of chemotherapy and immunotherapy. Postoperatively, if the investigator determines the patient may benefit, adjuvant therapy will be administered, consisting of 4 cycles of gemcitabine chemotherapy and maintenance immunotherapy with iparomlimab-toripalimab for up to 1 year. The primary endpoint is the R0 resection rate.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Maobin Meng(Co-Principal Investigator), PhD
- 電話番号:15202231270
- メール:mmeng@tmu.edu.cn
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years and ≤75 years, both genders.
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
- Radiographically assessed as borderline resectable pancreatic cancer according to NCCN guidelines.
- At least one measurable lesion per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ and bone marrow function.
- Expected survival ≥ 6 months.
- Voluntarily signed informed consent form.
Exclusion Criteria:
- Known distant metastases.
- Prior systemic anti-tumor therapy or radiotherapy for pancreatic cancer.
- Active autoimmune disease requiring systemic treatment within the past 2 years.
- History of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumor.
- Uncontrolled comorbid conditions, including but not limited to active infections, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Pregnant or lactating women.
- Any condition that, in the investigator's opinion, would make the subject unsuitable for participation in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Iparomlimab-Tuvonralimab + Gemcitabine Group
Participants will receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1) combined with Gemcitabine (1000 mg/m², IV, D1 and D8) every 3 weeks for up to 6 cycles. After 6 cycles, participants without disease progression and with acceptable tolerance may continue to receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1, every 3 weeks) as maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination. |
Iparomlimab/Tuvonralimab (Code: QL1706) is a bispecific antibody targeting PD-1 and CTLA-4. It is administered by intravenous infusion at a dose of XX mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Gemcitabine (Brand name: Gemzar) is a nucleoside analogue chemotherapeutic agent. It is administered by intravenous infusion at a dose of 1000 mg/m² on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues. It is administered in XX fractions over XX days/weeks. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate, ORR
時間枠:From first dose to disease progression or study completion, up to approximately 24 months
|
Objective Response Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR) or partial response (PR). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Incidence of Adverse Events
時間枠:From first dose to 90 days after last dose, up to approximately 27 months
|
Incidence and severity of adverse events assessed by CTCAE v5.0, including treatment-related adverse events (TRAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs). |
From first dose to 90 days after last dose, up to approximately 27 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease Control Rate, DCR
時間枠:From first dose to disease progression or study completion, up to approximately 24 months
|
Disease Control Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Progression-Free Survival, PFS
時間枠:From first dose to disease progression or death, up to approximately 24 months
|
Progression-Free Survival assessed by RECIST v1.1, defined as the time from first dose to the first documentation of disease progression or death from any cause. |
From first dose to disease progression or death, up to approximately 24 months
|
|
Overall Survival, OS
時間枠:From first dose to death or last follow-up, up to approximately 36 months
|
Defined as the time from first dose to death from any cause. |
From first dose to death or last follow-up, up to approximately 36 months
|
|
Duration of Response, DOR
時間枠:From first documentation of response to disease progression or death, up to approximately 24 months
|
Duration of Response assessed by RECIST v1.1, defined as the time from the first documentation of complete response (CR) or partial response (PR) to the first documentation of disease progression or death from any cause. |
From first documentation of response to disease progression or death, up to approximately 24 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation between Biomarkers and Clinical Efficacy
時間枠:From first dose to study completion, up to approximately 36 months
|
To explore the correlation between biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI) status in tumor tissue and clinical efficacy endpoints including ORR, PFS, and OS. |
From first dose to study completion, up to approximately 36 months
|
|
Quality of Life Assessment
時間枠:From baseline to 90 days after last dose, up to approximately 27 months
|
To evaluate changes in quality of life during and after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). |
From baseline to 90 days after last dose, up to approximately 27 months
|
|
Dynamic Changes of Peripheral Blood Immune Cell Subsets and Cytokines
時間枠:From first dose to disease progression or study completion, up to approximately 24 months
|
To explore the dynamic changes of peripheral blood immune cell subsets (CD3+, CD4+, CD8+ T cells, etc.) and cytokines (IL-6, TNF-α, IFN-γ, etc.) during treatment and their correlation with efficacy and adverse events. |
From first dose to disease progression or study completion, up to approximately 24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- TJSPAC-03
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This is a prospective, single-arm, single-center Phase II clinical study to evaluate the efficacy and safety of Iparomlimab/Tuvonralimab combined with gemcitabine in the treatment of locally advanced pancreatic cancer. The study plans to enroll 30 patients with histologically or cytologically confirmed locally advanced pancreatic ductal adenocarcinoma. Subjects will receive Iparomlimab/Tuvonralimab combined with gemcitabine until disease progression, intolerable toxicity, withdrawal of informed consent, or completion of 6 cycles of treatment. The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。